SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2014 Biotech Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates5/14/2014 6:25:25 AM
   of 487
 
From today's Ablynx quarterly report :

Outlook for the remainder of 2014
It is anticipated that top-line Phase II data from the TITAN study with caplacizumab will be reported in June 2014. The Phase II paediatric study with the anti-RSV Nanobody, ALX-0171, is expected to commence in Q4 2014. Data from the ALX-0061 s.c. Phase I study are planned to be available in Q4 2014.

Ablynx expects further advances in both pre-clinical and clinical stage partnered programmes during the rest of 2014, some of which may result in payment to the Company of milestones. Further progress is also expected in the search for partners in emerging markets for some of the Company’s clinical assets.

Initiation of new wholly-owned discovery programmes will continue, as will technology developments, both in-house and in collaboration with partners, to exploit the Nanobody platform even more broadly.

Finally, good cash management will remain a key priority for the Company, with a strong focus on net cash burn and the generation of cash to support the on-going development of the business. The Company expects to keep net cash burn in the €30-€35 million range for 2014.

(Cash stands at €200m; 49,083,327 shares outstanding)

Possible buying opportunity in June if caplacizumab results are a bust ?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News